RESPONSE
No coronary artery occlusion in septic shock: Isoproterenol infusion should not be discouraged Dear Editor, in their relevant letter, Dr Wiwanitkit pointed out important limitations about the use of isoproterenol: these authors should be commended for their input to our research. Indeed, in animal models of coronary occlusion, isoproterenol administration augmented infarct size (1) , suggesting that the use of isoproterenol in patients with coronary artery occlusion should be discouraged, probably in favor of the use of dobutamine in the same patients (2). However, in those models, isoproterenol was used as repeated boli of 0.15 mg/kg (i.e. 9 mg for 60 kg) in non-resuscitated animals, whereas in our patients we infused continuously a maximal dosage of 0.5 mg/h after well-conducted resuscitation.
Patients with septic shock do not suffer from coronary occlusion. Several experimental models suggest that septic shock induces an even increased coronary flow (3). In addition, betaadrenoreceptors are desensitized in patients with sepsis (4), supporting the need to introduce the most powerful beta-adrenergic inotrope in selected patients developing a septic acute heart failure (4, 5) . Finally, to date, both experimental models and cohorts of patients did not reveal harm associated with the use of isoproterenol in this indication (6, 7) . In conclusion, inotropes should be carefully used in few, selected patients. The harmful effect of isoproterenol in animals with coronary occlusion, however, should not discard its potential role in septic shock.
